RS57594B1 - Derivati pirazina za sprečavanje ili lečenje ataksičnog poremećaja - Google Patents

Derivati pirazina za sprečavanje ili lečenje ataksičnog poremećaja

Info

Publication number
RS57594B1
RS57594B1 RS20180927A RSP20180927A RS57594B1 RS 57594 B1 RS57594 B1 RS 57594B1 RS 20180927 A RS20180927 A RS 20180927A RS P20180927 A RSP20180927 A RS P20180927A RS 57594 B1 RS57594 B1 RS 57594B1
Authority
RS
Serbia
Prior art keywords
prevention
treatment
pyridazine derivatives
ataxic disorder
ataxic
Prior art date
Application number
RS20180927A
Other languages
English (en)
Inventor
Sarah Almond
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50554599&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS57594(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of RS57594B1 publication Critical patent/RS57594B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RS20180927A 2014-03-06 2015-03-06 Derivati pirazina za sprečavanje ili lečenje ataksičnog poremećaja RS57594B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1403944.0A GB201403944D0 (en) 2014-03-06 2014-03-06 New use
EP15709324.6A EP3113778B1 (en) 2014-03-06 2015-03-06 Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
PCT/GB2015/050654 WO2015132608A1 (en) 2014-03-06 2015-03-06 Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder

Publications (1)

Publication Number Publication Date
RS57594B1 true RS57594B1 (sr) 2018-11-30

Family

ID=50554599

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20180927A RS57594B1 (sr) 2014-03-06 2015-03-06 Derivati pirazina za sprečavanje ili lečenje ataksičnog poremećaja

Country Status (31)

Country Link
US (1) US20170014407A1 (sr)
EP (1) EP3113778B1 (sr)
JP (1) JP6510549B2 (sr)
KR (1) KR20160126081A (sr)
CN (1) CN106102743A (sr)
AU (1) AU2015225954B2 (sr)
CA (1) CA2940342A1 (sr)
CL (1) CL2016002151A1 (sr)
CY (1) CY1120573T1 (sr)
DK (1) DK3113778T3 (sr)
EA (1) EA036438B1 (sr)
ES (1) ES2676905T3 (sr)
GB (1) GB201403944D0 (sr)
GE (1) GEP20196984B (sr)
HR (1) HRP20181082T1 (sr)
IL (1) IL247435A0 (sr)
LT (1) LT3113778T (sr)
MA (1) MA39315A1 (sr)
MX (1) MX2016010524A (sr)
MY (1) MY186475A (sr)
PH (1) PH12016501751A1 (sr)
PL (1) PL3113778T3 (sr)
PT (1) PT3113778T (sr)
RS (1) RS57594B1 (sr)
SG (1) SG11201607106YA (sr)
SI (1) SI3113778T1 (sr)
TR (1) TR201809537T4 (sr)
TW (1) TW201534591A (sr)
UA (1) UA123352C2 (sr)
WO (1) WO2015132608A1 (sr)
ZA (1) ZA201604611B (sr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201222711D0 (en) 2012-12-17 2013-01-30 Takeda Pharmaceutical Novel compounds
AU2015253505B2 (en) 2014-04-29 2019-09-19 Fmc Corporation Pyridazinone herbicides
TWI785022B (zh) 2017-03-28 2022-12-01 美商富曼西公司 新穎噠嗪酮類除草劑
BR112019028016B1 (pt) 2017-06-30 2023-12-05 Fmc Corporation Composto, composições herbicidas, mistura herbicida e método para controlar o crescimento de vegetação indesejada
CN112569217B (zh) * 2019-09-30 2022-04-22 厦门大学 戊酸衍生物在治疗遗传性小脑共济失调中的应用
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
EP4301367A1 (en) 2021-03-01 2024-01-10 Takeda Pharmaceutical Company Limited Use of luvadaxistat for the treatment of cognitive impairment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2262322T3 (es) * 1998-06-10 2006-11-16 Meiji Seika Kaisha, Ltd. Tratamiento de la degenaracion espinocereberal y comoposiciones utiles para el tratamiento de degeneracion espinocerebelar.
WO2003047558A2 (en) * 2001-12-03 2003-06-12 Genset S.A. Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors
JO3115B1 (ar) * 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao

Also Published As

Publication number Publication date
IL247435A0 (en) 2016-11-30
KR20160126081A (ko) 2016-11-01
ZA201604611B (en) 2017-09-27
CA2940342A1 (en) 2015-09-11
EP3113778A1 (en) 2017-01-11
TW201534591A (zh) 2015-09-16
LT3113778T (lt) 2018-08-27
CN106102743A (zh) 2016-11-09
CL2016002151A1 (es) 2016-12-30
CY1120573T1 (el) 2019-07-10
DK3113778T3 (en) 2018-07-30
AU2015225954B2 (en) 2020-06-18
ES2676905T3 (es) 2018-07-26
MA39315A1 (fr) 2017-09-29
SG11201607106YA (en) 2016-09-29
GB201403944D0 (en) 2014-04-23
HRP20181082T1 (hr) 2018-09-07
JP2017507156A (ja) 2017-03-16
SI3113778T1 (en) 2018-08-31
MX2016010524A (es) 2016-10-31
EA036438B1 (ru) 2020-11-11
JP6510549B2 (ja) 2019-05-08
MY186475A (en) 2021-07-22
EA201691566A1 (ru) 2016-12-30
PH12016501751A1 (en) 2017-02-06
PT3113778T (pt) 2018-07-11
AU2015225954A1 (en) 2016-07-07
EP3113778B1 (en) 2018-06-06
UA123352C2 (uk) 2021-03-24
TR201809537T4 (tr) 2018-07-23
WO2015132608A1 (en) 2015-09-11
PL3113778T3 (pl) 2018-11-30
GEP20196984B (en) 2019-06-25
US20170014407A1 (en) 2017-01-19

Similar Documents

Publication Publication Date Title
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
PL3157512T3 (pl) Zastosowanie kannabidioli w leczeniu padaczki
GB201411496D0 (en) Use of 7-Oh-Cannabidiol (7-Oh-CBD) and/or 7-Oh-Cannabidvarin (7-Oh-CBDV) in the treatment of epilepsy
HRP20190194T1 (hr) 17a,21-diesteri korteksolona, namijenjeni liječenju tumora
IL247435A0 (en) Pyridazine derivatives for use in the prevention of or treatment of ataxic disorder
IL251905A0 (en) Epilimod for use in the treatment of kidney cancer
IL251903B (en) Epilimod for use in the treatment of colon cancer
IL252493B (en) Compounds for use in the prevention or treatment of cancer
GB201511772D0 (en) Improvements in the treatment of ash
GB201415876D0 (en) Methods for the treatment and prevention of Ebola